Global epidemiology of systemic lupus erythematosus

MRW Barber, C Drenkard, T Falasinnu, A Hoi… - Nature Reviews …, 2021 - nature.com
Systemic lupus erythematosus (SLE) is an autoimmune disease with protean manifestations
that predominantly affects young women. Certain ethnic groups are more vulnerable than …

Lupus nephritis

HJ Anders, R Saxena, M Zhao, I Parodis… - Nature reviews Disease …, 2020 - nature.com
Lupus nephritis (LN) is a form of glomerulonephritis that constitutes one of the most severe
organ manifestations of the autoimmune disease systemic lupus erythematosus (SLE). Most …

Systemic lupus erythematosus: diagnosis and clinical management

A Fava, M Petri - Journal of autoimmunity, 2019 - Elsevier
Systemic lupus erythematosus (SLE) is a worldwide chronic autoimmune disease which
may affect every organ and tissue. Genetic predisposition, environmental triggers, and the …

Management strategies and future directions for systemic lupus erythematosus in adults

L Durcan, T O'Dwyer, M Petri - The Lancet, 2019 - thelancet.com
Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by the loss of
self-tolerance and formation of nuclear autoantigens and immune complexes resulting in …

New insights into the immunopathogenesis of systemic lupus erythematosus

GC Tsokos, MS Lo, PC Reis, KE Sullivan - Nature Reviews …, 2016 - nature.com
The aetiology of systemic lupus erythematosus (SLE) is multifactorial, and includes
contributions from the environment, stochastic factors, and genetic susceptibility. Great gains …

Update on lupus nephritis

S Almaani, A Meara, BH Rovin - … Journal of the American Society of …, 2017 - journals.lww.com
SLE is a chronic inflammatory disease that affects the kidneys in about 50% of patients.
Lupus nephritis is a major risk factor for overall morbidity and mortality in SLE, and despite …

[PDF][PDF] Anifrolumab, an anti–interferon‐α receptor monoclonal antibody, in moderate‐to‐severe systemic lupus erythematosus

R Furie, M Khamashta, JT Merrill… - Arthritis & …, 2017 - Wiley Online Library
Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor
antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with …

Personalized immunomonitoring uncovers molecular networks that stratify lupus patients

R Banchereau, S Hong, B Cantarel, N Baldwin… - Cell, 2016 - cell.com
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by loss of
tolerance to nucleic acids and highly diverse clinical manifestations. To assess its molecular …

The global burden of SLE: prevalence, health disparities and socioeconomic impact

EE Carter, SG Barr, AE Clarke - Nature reviews rheumatology, 2016 - nature.com
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that can
potentially lead to serious organ complications and even death. Its global burden—in terms …

The frequency and outcome of lupus nephritis: results from an international inception cohort study

JG Hanly, AG O'Keeffe, L Su, MB Urowitz… - …, 2016 - academic.oup.com
Objective. To determine nephritis outcomes in a prospective multi-ethnic/racial SLE
inception cohort. Methods. Patients in the Systemic Lupus International Collaborating Clinics …